ROCK platform

Search documents
Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
Globenewswireยท 2025-04-21 10:30
Core Points - Affimed N.V. has received a notice from Nasdaq indicating that its common shares have closed below the minimum bid price of $1.00 for the last 30 consecutive business days [1] - The company has until October 13, 2025, to regain compliance with the Minimum Bid Price Rule, with the possibility of transferring to the Nasdaq Capital Market for an additional 180 days if necessary [2] - The notice does not have an immediate effect on the listing or trading of the company's shares, and the company plans to monitor its bid price and explore options for compliance [3] Company Overview - Affimed N.V. is a clinical-stage immuno-oncology company focused on harnessing the innate immune system to combat cancer through its proprietary innate cell engagers (ICE) [4] - The company is headquartered in Mannheim, Germany, and is led by a team of experienced biotechnology and pharmaceutical professionals [4]